Upadacitinib in Crohn's disease
Expert Opin Pharmacother. 2024 Mar 21. doi: 10.1080/14656566.2024.2333964. Online ahead of print.ABSTRACTINTRODUCTION: The small molecule and oral selective and reversible Janus kinase (JAK) inhibitor upadacitinib has been approved for the treatment of moderate to severe active Crohn's disease (CD) in adult patients since April 2023 by EMA/FDA.AREAS COVERED: The approval is based on the two induction studies a maintenance study showing that upadacitinib induction and maintenance therapy was superior to placebo. The approval of upadacitinib in CD expands the therapeutic armamentarium for the management of inflammatory bowel...
Source: Expert Opinion on Pharmacotherapy - March 21, 2024 Category: Drugs & Pharmacology Authors: Axel Dignass Philip Esters Cathrin Flauaus Source Type: research
Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials
Expert Rev Gastroenterol Hepatol. 2024 Jan-Feb;18(1-3):73-87. doi: 10.1080/17474124.2024.2326838. Epub 2024 Mar 21.ABSTRACTINTRODUCTION: Treatment goals for ulcerative colitis (UC) are evolving from the achievement of clinical remission to more rigorous goals defined by endoscopic and histologic healing. Achievement of deeper remission targets aims to reduce the risk of colectomy, hospitalizations, and colorectal cancer.AREAS COVERED: This review covers histologic assessments, histologic remission as a clinical trial endpoint, and the association between histologic disease activity and clinical outcomes. Future directions ...
Source: Expert Review of Gastroenterology and Hepatology - March 21, 2024 Category: Gastroenterology Authors: Rish K Pai Geert D'Haens Taku Kobayashi Bruce E Sands Simon Travis Vipul Jairath Gert De Hertogh Bomina Park Kim McGinnis Isabel Redondo Nicole G Lipitz Theresa Hunter Gibble Fernando Magro Source Type: research
Cytokine and chemokine profiles in ulcerative colitis relapse after coronavirus disease 2019 vaccination
J Clin Biochem Nutr. 2024 Mar;74(2):127-135. doi: 10.3164/jcbn.23-26. Epub 2023 Sep 16.ABSTRACTCoronavirus disease 2019 (COVID-19) vaccines are highly effective; however, vaccine-related adverse events, including autoimmunity, have been reported. Case reports describing relapse or new-onset of ulcerative colitis (UC) after COVID-19 mRNA vaccination are available. However, the molecular mechanisms underlying the development of colonic inflammation associated with COVID-19 mRNA vaccination are poorly understood. Furthermore, it is unclear whether the relapse of UC after COVID-19 vaccination is driven by unique cytokine respo...
Source: Clinical Biochemistry - March 21, 2024 Category: Biochemistry Authors: Yasuhiro Masuta Kosuke Minaga Yasuo Otsuka Natsuki Okai Akane Hara Sho Masaki Tomoyuki Nagai Hajime Honjo Masatoshi Kudo Tomohiro Watanabe Source Type: research
Crosstalk between NOD2 and TLR2 suppresses the development of TLR2-mediated experimental colitis
J Clin Biochem Nutr. 2024 Mar;74(2):146-153. doi: 10.3164/jcbn.23-87. Epub 2023 Dec 15.ABSTRACTNucleotide-binding oligomerization domain 2 (NOD2) is an intracellular sensor for muramyl dipeptide (MDP), a degradation product of bacterial cell wall peptidoglycan (PGN). PGN stimulates cell-surface Toll-like receptor 2 (TLR2) independently of NOD2, indicating the presence of crosstalk between extracellular TLR2 and intracellular NOD2 upon exposure to PGN. NOD2-deficient mice were sensitive, while TLR2-deficient mice were resistant to experimental colitis induced by intrarectal administration of PGN. Severe colitis in NOD2-defi...
Source: Clinical Biochemistry - March 21, 2024 Category: Biochemistry Authors: Natsuki Okai Yasuhiro Masuta Yasuo Otsuka Akane Hara Sho Masaki Ken Kamata Kosuke Minaga Hajime Honjo Masatoshi Kudo Tomohiro Watanabe Source Type: research
Assessing the economics of biologic and small molecule therapies for the treatment of moderate to severe ulcerative colitis in Japan: a cost per responder analysis of upadacitinib
CONCLUSIONS: The results of this cost per responder analysis suggest upadacitinib is a cost-effective option for the first- and second-line treatment of moderately to severely active ulcerative colitis in Japan.PMID:38512101 | DOI:10.1080/13696998.2024.2333683 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 21, 2024 Category: Health Management Authors: Masayuki Saruta Isao Kawaguchi Yuji Ogawa Yuri Sanchez Gonzalez Naoki Numajiri Xiaohe Tang Russell Miller Source Type: research
Cytokine and chemokine profiles in ulcerative colitis relapse after coronavirus disease 2019 vaccination
J Clin Biochem Nutr. 2024 Mar;74(2):127-135. doi: 10.3164/jcbn.23-26. Epub 2023 Sep 16.ABSTRACTCoronavirus disease 2019 (COVID-19) vaccines are highly effective; however, vaccine-related adverse events, including autoimmunity, have been reported. Case reports describing relapse or new-onset of ulcerative colitis (UC) after COVID-19 mRNA vaccination are available. However, the molecular mechanisms underlying the development of colonic inflammation associated with COVID-19 mRNA vaccination are poorly understood. Furthermore, it is unclear whether the relapse of UC after COVID-19 vaccination is driven by unique cytokine respo...
Source: Journal of Clinical Biochemistry and Nutrition - March 21, 2024 Category: Nutrition Authors: Yasuhiro Masuta Kosuke Minaga Yasuo Otsuka Natsuki Okai Akane Hara Sho Masaki Tomoyuki Nagai Hajime Honjo Masatoshi Kudo Tomohiro Watanabe Source Type: research
Crosstalk between NOD2 and TLR2 suppresses the development of TLR2-mediated experimental colitis
J Clin Biochem Nutr. 2024 Mar;74(2):146-153. doi: 10.3164/jcbn.23-87. Epub 2023 Dec 15.ABSTRACTNucleotide-binding oligomerization domain 2 (NOD2) is an intracellular sensor for muramyl dipeptide (MDP), a degradation product of bacterial cell wall peptidoglycan (PGN). PGN stimulates cell-surface Toll-like receptor 2 (TLR2) independently of NOD2, indicating the presence of crosstalk between extracellular TLR2 and intracellular NOD2 upon exposure to PGN. NOD2-deficient mice were sensitive, while TLR2-deficient mice were resistant to experimental colitis induced by intrarectal administration of PGN. Severe colitis in NOD2-defi...
Source: Journal of Clinical Biochemistry and Nutrition - March 21, 2024 Category: Nutrition Authors: Natsuki Okai Yasuhiro Masuta Yasuo Otsuka Akane Hara Sho Masaki Ken Kamata Kosuke Minaga Hajime Honjo Masatoshi Kudo Tomohiro Watanabe Source Type: research
Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials
Expert Rev Gastroenterol Hepatol. 2024 Jan-Feb;18(1-3):73-87. doi: 10.1080/17474124.2024.2326838. Epub 2024 Mar 21.ABSTRACTINTRODUCTION: Treatment goals for ulcerative colitis (UC) are evolving from the achievement of clinical remission to more rigorous goals defined by endoscopic and histologic healing. Achievement of deeper remission targets aims to reduce the risk of colectomy, hospitalizations, and colorectal cancer.AREAS COVERED: This review covers histologic assessments, histologic remission as a clinical trial endpoint, and the association between histologic disease activity and clinical outcomes. Future directions ...
Source: Expert Review of Gastroenterology and Hepatology - March 21, 2024 Category: Gastroenterology Authors: Rish K Pai Geert D'Haens Taku Kobayashi Bruce E Sands Simon Travis Vipul Jairath Gert De Hertogh Bomina Park Kim McGinnis Isabel Redondo Nicole G Lipitz Theresa Hunter Gibble Fernando Magro Source Type: research
Cytokine and chemokine profiles in ulcerative colitis relapse after coronavirus disease 2019 vaccination
J Clin Biochem Nutr. 2024 Mar;74(2):127-135. doi: 10.3164/jcbn.23-26. Epub 2023 Sep 16.ABSTRACTCoronavirus disease 2019 (COVID-19) vaccines are highly effective; however, vaccine-related adverse events, including autoimmunity, have been reported. Case reports describing relapse or new-onset of ulcerative colitis (UC) after COVID-19 mRNA vaccination are available. However, the molecular mechanisms underlying the development of colonic inflammation associated with COVID-19 mRNA vaccination are poorly understood. Furthermore, it is unclear whether the relapse of UC after COVID-19 vaccination is driven by unique cytokine respo...
Source: Clinical Biochemistry - March 21, 2024 Category: Biochemistry Authors: Yasuhiro Masuta Kosuke Minaga Yasuo Otsuka Natsuki Okai Akane Hara Sho Masaki Tomoyuki Nagai Hajime Honjo Masatoshi Kudo Tomohiro Watanabe Source Type: research
Crosstalk between NOD2 and TLR2 suppresses the development of TLR2-mediated experimental colitis
J Clin Biochem Nutr. 2024 Mar;74(2):146-153. doi: 10.3164/jcbn.23-87. Epub 2023 Dec 15.ABSTRACTNucleotide-binding oligomerization domain 2 (NOD2) is an intracellular sensor for muramyl dipeptide (MDP), a degradation product of bacterial cell wall peptidoglycan (PGN). PGN stimulates cell-surface Toll-like receptor 2 (TLR2) independently of NOD2, indicating the presence of crosstalk between extracellular TLR2 and intracellular NOD2 upon exposure to PGN. NOD2-deficient mice were sensitive, while TLR2-deficient mice were resistant to experimental colitis induced by intrarectal administration of PGN. Severe colitis in NOD2-defi...
Source: Clinical Biochemistry - March 21, 2024 Category: Biochemistry Authors: Natsuki Okai Yasuhiro Masuta Yasuo Otsuka Akane Hara Sho Masaki Ken Kamata Kosuke Minaga Hajime Honjo Masatoshi Kudo Tomohiro Watanabe Source Type: research
Assessing the economics of biologic and small molecule therapies for the treatment of moderate to severe ulcerative colitis in Japan: a cost per responder analysis of upadacitinib
CONCLUSIONS: The results of this cost per responder analysis suggest upadacitinib is a cost-effective option for the first- and second-line treatment of moderately to severely active ulcerative colitis in Japan.PMID:38512101 | DOI:10.1080/13696998.2024.2333683 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 21, 2024 Category: Health Management Authors: Masayuki Saruta Isao Kawaguchi Yuji Ogawa Yuri Sanchez Gonzalez Naoki Numajiri Xiaohe Tang Russell Miller Source Type: research
Cytokine and chemokine profiles in ulcerative colitis relapse after coronavirus disease 2019 vaccination
J Clin Biochem Nutr. 2024 Mar;74(2):127-135. doi: 10.3164/jcbn.23-26. Epub 2023 Sep 16.ABSTRACTCoronavirus disease 2019 (COVID-19) vaccines are highly effective; however, vaccine-related adverse events, including autoimmunity, have been reported. Case reports describing relapse or new-onset of ulcerative colitis (UC) after COVID-19 mRNA vaccination are available. However, the molecular mechanisms underlying the development of colonic inflammation associated with COVID-19 mRNA vaccination are poorly understood. Furthermore, it is unclear whether the relapse of UC after COVID-19 vaccination is driven by unique cytokine respo...
Source: Journal of Clinical Biochemistry and Nutrition - March 21, 2024 Category: Nutrition Authors: Yasuhiro Masuta Kosuke Minaga Yasuo Otsuka Natsuki Okai Akane Hara Sho Masaki Tomoyuki Nagai Hajime Honjo Masatoshi Kudo Tomohiro Watanabe Source Type: research
Crosstalk between NOD2 and TLR2 suppresses the development of TLR2-mediated experimental colitis
J Clin Biochem Nutr. 2024 Mar;74(2):146-153. doi: 10.3164/jcbn.23-87. Epub 2023 Dec 15.ABSTRACTNucleotide-binding oligomerization domain 2 (NOD2) is an intracellular sensor for muramyl dipeptide (MDP), a degradation product of bacterial cell wall peptidoglycan (PGN). PGN stimulates cell-surface Toll-like receptor 2 (TLR2) independently of NOD2, indicating the presence of crosstalk between extracellular TLR2 and intracellular NOD2 upon exposure to PGN. NOD2-deficient mice were sensitive, while TLR2-deficient mice were resistant to experimental colitis induced by intrarectal administration of PGN. Severe colitis in NOD2-defi...
Source: Journal of Clinical Biochemistry and Nutrition - March 21, 2024 Category: Nutrition Authors: Natsuki Okai Yasuhiro Masuta Yasuo Otsuka Akane Hara Sho Masaki Ken Kamata Kosuke Minaga Hajime Honjo Masatoshi Kudo Tomohiro Watanabe Source Type: research
Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials
Expert Rev Gastroenterol Hepatol. 2024 Jan-Feb;18(1-3):73-87. doi: 10.1080/17474124.2024.2326838. Epub 2024 Mar 21.ABSTRACTINTRODUCTION: Treatment goals for ulcerative colitis (UC) are evolving from the achievement of clinical remission to more rigorous goals defined by endoscopic and histologic healing. Achievement of deeper remission targets aims to reduce the risk of colectomy, hospitalizations, and colorectal cancer.AREAS COVERED: This review covers histologic assessments, histologic remission as a clinical trial endpoint, and the association between histologic disease activity and clinical outcomes. Future directions ...
Source: Expert Review of Gastroenterology and Hepatology - March 21, 2024 Category: Gastroenterology Authors: Rish K Pai Geert D'Haens Taku Kobayashi Bruce E Sands Simon Travis Vipul Jairath Gert De Hertogh Bomina Park Kim McGinnis Isabel Redondo Nicole G Lipitz Theresa Hunter Gibble Fernando Magro Source Type: research
Assessing the economics of biologic and small molecule therapies for the treatment of moderate to severe ulcerative colitis in Japan: a cost per responder analysis of upadacitinib
CONCLUSIONS: The results of this cost per responder analysis suggest upadacitinib is a cost-effective option for the first- and second-line treatment of moderately to severely active ulcerative colitis in Japan.PMID:38512101 | DOI:10.1080/13696998.2024.2333683 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 21, 2024 Category: Health Management Authors: Masayuki Saruta Isao Kawaguchi Yuji Ogawa Yuri Sanchez Gonzalez Naoki Numajiri Xiaohe Tang Russell Miller Source Type: research
